MedTrace Logo

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

NCT02713880 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-10

No results posted yet for this study

Summary

International, multicenter, observational, longitudinal study to identify biomarker/s for the development of a new MS-based biomarker for the early and sensitive diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood and number of correctly identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy

Conditions

  • Transthyretin Amyloidosis
  • Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
  • Transthyretin Amyloid Cardiopathy

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Arndt Rolfs, Prof. · CENTOGENE GmbH Rostock

Eligibility

Min Age
2 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2019-12-01
Completion
2019-12-01

Countries

  • Germany
  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02713880 on ClinicalTrials.gov